Bicycle Therapeutics (BCYC)
| Bid | 6.5 |
| Market Cap | 540.41M |
| Revenue (ttm) | 35.27M |
| Net Income (ttm) | -169.06M |
| EPS (ttm) | -2.9 |
| PE Ratio (ttm) | -2.7 |
| Forward PE | -3.67 |
| Analyst | Buy |
| Ask | 9 |
| Volume | 596,233 |
| Avg. Volume (20D) | 333,090 |
| Open | 7.28 |
| Previous Close | 7.07 |
| Day's Range | 7.38 - 7.99 |
| 52-Week Range | 6.10 - 28.67 |
| Beta | 1.40 |
About BCYC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial ...
Analyst Forecast
According to 9 analyst ratings, the average rating for BCYC stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 257.83% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Bicycle Therapeutics: Trading At Cash, Underwhelming But Not Unsalvageable DataBicycle Therapeutics' BT8009 showed promising efficacy and safety in early trials, but mixed results in combination with Keytruda caused significant stock volatility. BT8009 demonstrated a superior sa...